The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Open accessAbstract
Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and deliver a highly potent cytotoxic agent. The synergistic combination of mAbs conjugated to small-molecule chemotherapeutics, via a stable linker, has given rise to an extremely efficacious class of anti-cancer drugs with an already large and rapidly growing clinical pipeline. The primary objective of this paper is to review current knowledge and latest developments in the field of ADCs. Upon intravenous administration, ADCs bind to their target antigens and are internalized through receptor-mediated endocytosis. This facilitates the subsequent release of the cytotoxin, which eventually leads to apoptotic cell death of the cancer cell. The three components of ADCs (mAb, linker and cytotoxin) affect the efficacy and toxicity of the conjugate. Optimizing each one, while enhancing the functionality of the ADC as a whole, has been one of the major considerations of ADC design and development. In addition to these, the choice of clinically relevant targets and the position and number of linkages have also been the key determinants of ADC efficacy. The only marketed ADCs, brentuximab vedotin and trastuzumab emtansine (T-DM1), have demonstrated their use against both haematological and solid malignancies respectively. The success of future ADCs relies on improving target selection, increasing cytotoxin potency, developing innovative linkers and overcoming drug resistance. As more research is conducted to tackle these issues, ADCs are likely to become part of the future of targeted cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“ADCs that bind to neovasculature destroy the tumour blood supply and cause tumour cell death via nutrient deprivation and hypoxia [75] [76].”
BackgroundTissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Microtubule assembly, organization and dynamics in axons and dendrites
Conde, C., & Cáceres, A. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2631 · Cited by 1,086
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordán, J., Bellacosa, A., Tsichlis, P. N., & Hay, N. (1997) · Genes & Development · doi:10.1101/gad.11.6.701 · Cited by 1,074
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
The role of glutathione in cancer
Balendiran, G. K., Dabur, R., & Fraser, D. (2004) · Cell Biochemistry and Function · doi:10.1002/cbf.1149 · Cited by 927
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 815
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Antibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Therapeutic antibody targeting of individual Notch receptors
Wu, Y., Cain-Hom, C., Choy, L., Hagenbeek, T. J., de Leon, G. P., Chen, Y., Finkle, D., Venook, R., Wu, X., Ridgway, J., et al. (2010) · Nature · doi:10.1038/nature08878 · Cited by 720
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
Wang, L., & Schultz, P. G. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200460627 · Cited by 651
Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology
Chalker, J. M., Bernardes, G. J. L., Lin, Y. A., & Davis, B. G. (2009) · Chemistry – An Asian Journal · doi:10.1002/asia.200800427 · Cited by 649
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Ducry, L., & Stump, B. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9002019 · Cited by 625
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
Properties and applications of microbial transglutaminase
Yokoyama, K., Nio, N., & Kikuchi, Y. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1539-5 · Cited by 605
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
Mahadevan, D., & Von Hoff, D. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0686 · Cited by 601
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Axup, J. Y., Bajjuri, K. M., Ritland, M., Hutchins, B. M., Kim, C. H., Kazane, S. A., Halder, R., Forsyth, J. S., Santidrian, A. F., Stafin, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211023109 · Cited by 596
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Unraveling the role of proteases in cancer
Koblinski, J. E., Ahram, M., & Sloane, B. F. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(99)00224-7 · Cited by 580
Strop, P., Liu, S.-H., Dorywalska, M., Delaria, K., Dushin, R. G., Tran, T.-T., Ho, W.-H., Farias, S., Casas, M. G., Abdiche, Y., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.01.010 · Cited by 505
Rubin, I., & Yarden, Y. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s3 · Cited by 500
Recent advances in tumor-targeting anticancer drug conjugates
Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.084 · Cited by 490
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Monoclonal antibody therapeutics: history and future
Buss, N. A., Henderson, S. J., McFarlane, M., Shenton, J. M., & de Haan, L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.08.001 · Cited by 434
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, N. M., Miyamoto, J. B., Zhang, X., Sanderson, R. J., Benjamin, D. R., Sievers, E. L., Senter, P. D., & Alley, S. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2069 · Cited by 393
Genetic incorporation of unnatural amino acids into proteins in mammalian cells
Liu, W., Brock, A., Chen, S., Chen, S., & Schultz, P. G. (2007) · Nature Methods · doi:10.1038/nmeth1016 · Cited by 373
Katz, J., Janik, J. E., & Younes, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0488 · Cited by 368
Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J. P., Weiner, L. M., Marks, J. D., & Adams, G. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2277 · Cited by 365
Zimmerman, E. S., Heibeck, T. H., Gill, A., Li, X., Murray, C. J., Madlansacay, M. R., Tran, C., Uter, N. T., Yin, G., Rivers, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400490z · Cited by 363
DiJoseph, J. F., Armellino, D. C., Boghaert, E. R., Khandke, K., Dougher, M. M., Sridharan, L., Kunz, A., Hamann, P. R., Gorovits, B., Udata, C., et al. (2004) · Blood · doi:10.1182/blood-2003-07-2466 · Cited by 361
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Selenocysteine in proteins—properties and biotechnological use
Johansson, L., Gafvelin, G., & Arnér, E. S. J. (2005) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.05.010 · Cited by 352
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Jeger, S., Zimmermann, K., Blanc, A., Grünberg, J., Honer, M., Hunziker, P., Struthers, H., & Schibli, R. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004243 · Cited by 344
The initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Ricart, A. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0486 · Cited by 332
Zhou, S.-F., Wang, L.-L., Di, Y., Xue, C., Duan, W., Li, C., & Li, Y. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785132870 · Cited by 318
Ritchie, M., Tchistiakova, L., & Scott, N. (2013) · mAbs · doi:10.4161/mabs.22854 · Cited by 312
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Dennler, P., Chiotellis, A., Fischer, E., Brégeon, D., Belmant, C., Gauthier, L., Lhospice, F., Romagne, F., & Schibli, R. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400574z · Cited by 292
Junutula, J. R., Flagella, K. M., Graham, R. A., Parsons, K. L., Ha, E., Raab, H., Bhakta, S., Nguyen, T., Dugger, D. L., Li, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0987 · Cited by 292
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Dubowchik, G. M., & Walker, M. A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00018-2 · Cited by 277
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Complement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice
Borvak, J. (1998) · International Immunology · doi:10.1093/intimm/10.9.1289 · Cited by 254
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 250
Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
Ellis, L. M., & Hicklin, D. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1070 · Cited by 248
Cell killing by antibody–drug conjugates
Kovtun, Y. V., & Goldmacher, V. S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.010 · Cited by 246
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
Sharkey, R. M., & Goldenberg, D. M. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.4.226 · Cited by 242
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
Natsume, A., Niwa, R., & Satoh, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s4378 · Cited by 233
Dostalek, M., Gardner, I., Gurbaxani, B. M., Rose, R. H., & Chetty, M. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-012-0027-4 · Cited by 230
Database of T cell-defined human tumor antigens: the 2013 update.
Vigneron, N., Stroobant, V., den Eynde, B. J. V., & van der Bruggen, P. (2013) · Europe PMC (PubMed Central) · Cited by 226
Schwartz, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048021 · Cited by 221
Almagro, J. C., & Fransson, J. (2008) · PubMed · doi:10.2741/2786 · Cited by 220
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 219
Boger, D. L., & Johnson, D. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3642 · Cited by 217
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Drug-conjugated monoclonal antibodies for the treatment of cancer
LAMBERT, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.017 · Cited by 210
Antibody–drug conjugates: Basic concepts, examples and future perspectives
Casi, G., & Neri, D. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.026 · Cited by 210
Ikeda, H., Hideshima, T., Fulciniti, M., Lutz, R. J., Yasui, H., Okawa, Y., Kiziltepe, T., Vallet, S., Pozzi, S., Santo, L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2867 · Cited by 203
Poon, K. A., Flagella, K., Beyer, J., Tibbitts, J., Kaur, S., Saad, O., Yi, J.-H., Girish, S., Dybdal, N., & Reynolds, T. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.09.003 · Cited by 198
Hamel, E. (1992) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(92)90028-x · Cited by 186
Petersdorf, S., Kopecky, K., Stuart, R. K., Larson, R. A., Nevill, T. J., Stenke, L., Slovak, M. L., Tallman, M. S., Willman, C. L., Erba, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.790.790 · Cited by 184
Synthesis and assembly of a full‐length human monoclonal antibody in algal chloroplasts
Tran, M., Zhou, B., Pettersson, P. L., Gonzalez, M. J., & Mayfield, S. P. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22446 · Cited by 182
Programmed cell death (apoptosis) and response to anti-cancer drugs
Smets, L. A. (1994) · Anti-Cancer Drugs · doi:10.1097/00001813-199402000-00001 · Cited by 179
Novel Peptide Linkers for Highly Potent Antibody−Auristatin Conjugate
Doronina, S. O., Bovee, T. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Morris-Tilden, C. A., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800289a · Cited by 179
Antibody-drug conjugates: Present and future
Beck, A., & Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.27436 · Cited by 176
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Function, evolution and structure of multidrug resistance protein (MRP)
Deeley, R. G., & Cole, S. P. C. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0070 · Cited by 173
Methods for site-specific drug conjugation to antibodies
Behrens, C. R., & Liu, B. (2014) · mAbs · doi:10.4161/mabs.26632 · Cited by 171
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R. J., & Lambert, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0485 · Cited by 170
Monoclonal antibodies in the clinic
Reichert, J. M. (2001) · Nature Biotechnology · doi:10.1038/nbt0901-819 · Cited by 168
Antibody Engineering for the Development of Therapeutic Antibodies
Kim, S. J., Park, Y., & Hong, H. J. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)25245-0 · Cited by 167
Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
Dosio, F., Brusa, P., & Cattel, L. (2011) · Toxins · doi:10.3390/toxins3070848 · Cited by 166
Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., & Lowman, H. B. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.12.011 · Cited by 165
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC.
Natsume, A., Niwa, R., & Satoh, M. (2009) · PubMed Central · Cited by 165
Oroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., Kovtun, Y., Chari, R., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0645 · Cited by 164
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window
Malhotra, V., & Perry, M. C. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.199 · Cited by 163
Monoclonal antibody therapy for solid tumors
Green, M. C., Murray, J. L., & Hortobágyi, G. N. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0176 · Cited by 157
Walter, R. B., Raden, B. W., Kamikura, D. M., Cooper, J. A., & Bernstein, I. D. (2004) · Blood · doi:10.1182/blood-2004-07-2784 · Cited by 155
Anti-cancer therapies targeting the tumor stroma
Hofmeister, V., Schrama, D., & Becker, J. C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0365-5 · Cited by 155
Linker Technologies for Antibody–Drug Conjugates
Nolting, B. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-541-5_5 · Cited by 154
Drug‐conjugated antibodies for the treatment of cancer
Lambert, J. M. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12044 · Cited by 153
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 147
Antibody-Drug Conjugate Targets
Teicher, B. A. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909790192365 · Cited by 142
Liberato, N. L., Marchetti, M., & Barosi, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4220 · Cited by 138
Human IgG2 Can Form Covalent Dimers
Yoo, E. M., Wims, L. A., Chan, L. A., & Morrison, S. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3134 · Cited by 126
Biological impediments to monoclonal antibody–based cancer immunotherapy
Christiansen, J., & Rajasekaran, A. K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1493.3.11 · Cited by 125
The future of antibodies as cancer drugs
Reichert, J. M., & Dhimolea, E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.006 · Cited by 125
Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy
Shapiro, P. S. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795538 · Cited by 124
Insights on P-Glycoprotein’s Efflux Mechanism Obtained by Molecular Dynamics Simulations
Ferreira, R. J., Ferreira, M. U., & dos Santos, D. J. V. A. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300083m · Cited by 123
Bispecific antibodies rise again
Garber, K. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4478 · Cited by 122
Multidrug Resistance: Can New Drugs Help Chemotherapy Score Against Cancer?
Goldman, B. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.255 · Cited by 118
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117
Vaklavas, C., & Forero, A. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712443076 · Cited by 115
Conjugation of Anticancer Drugs Through Endogenous Monoclonal Antibody Cysteine Residues
Lyon, R. P., Meyer, D. L., Setter, J. R., & Senter, P. D. (2011) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-416039-2.00006-9 · Cited by 111
The development of immunoconjugates for targeted cancer therapy
Smaglo, B. G., Aldeghaither, D. S., & Weiner, L. M. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.159 · Cited by 109
Lapusan, S., Vídriales, M., Thomas, X., de Botton, S., Vekhoff, A., Tang, R., Dumontet, C., Morariu-Zamfir, R., Lambert, J. M., Ozoux, M., et al. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9670-0 · Cited by 108
Bernstein, I. D. (2000) · Leukemia · doi:10.1038/sj.leu.2401663 · Cited by 105
Molecularly Defined Antibody Conjugation through a Selenocysteine Interface
Höfer, T., Skeffington, L. R., Chapman, C. M., & Rader, C. M. (2009) · Biochemistry · doi:10.1021/bi901744t · Cited by 104
Anti-CD30 diabody-drug conjugates with potent antitumor activity
Kim, K. M., McDonagh, C. F., Westendorf, L., Brown, L. L., Sussman, D. R., Feist, T., Lyon, R. P., Alley, S. C., Okeley, N. M., Zhang, X., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0388 · Cited by 99
Novel Therapeutic Strategies to Selectively Kill Cancer Cells
Panchal, R. G. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00240-2 · Cited by 99
Antibody Drug Conjugates as Cancer Therapeutics
Trail, P. A. (2013) · Antibodies · doi:10.3390/antib2010113 · Cited by 97
Site specific protein labeling by enzymatic posttranslational modification
Sünbül, M., & Yin, J. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b908687k · Cited by 95
Jenkins, T. C., Hurley, L. H., Neidle, S., & Thurston, D. E. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00052a012 · Cited by 90
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
Polson, A. G., Williams, M. B., Gray, A. M., Fuji, R. N., Poon, K. A., McBride, J., Raab, H. E., Januario, T., Go, M. A. T., Lau, J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.141 · Cited by 88
Approved monoclonal antibodies for cancer therapy
Boyiadzis, M. M., & Foon, K. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1151 · Cited by 87
Gerber, H., Sutherland, M. K., Stone, I. J., Morris-Tilden, C. A., Miyamoto, J. B., McCormick, R. S., Alley, S. C., Okeley, N. M., Hayes, B., Hernandez‐Ilizaliturri, F. J., et al. (2009) · Blood · doi:10.1182/blood-2008-09-179143 · Cited by 85
Conjugation Site Heterogeneity Causes Variable Electrostatic Properties in Fc Conjugates
Boylan, N. J., Zhou, W., Proos, R. J., Tolbert, T. J., Wolfe, J. L., & Laurence, J. S. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4000564 · Cited by 85
Patil, R., Portilla‐Arias, J., Ding, H., Konda, B. M., Rekechenetskiy, A., Inoue, S., Black, K. L., Holler, E., & Ljubimova, J. Y. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911681 · Cited by 83
Antibody drug conjugates — Trojan horses in the war on cancer
Iyer, U. G., & Kadambi, V. J. (2011) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2011.07.005 · Cited by 80
Rahman, K. M., Thompson, A. S., James, C., Narayanaswamy, M., & Thurston, D. E. (2009) · Journal of the American Chemical Society · doi:10.1021/ja902986x · Cited by 78
Antibody–drug conjugates: an emerging modality for the treatment of cancer
Leal, M., Sapra, P., Hurvitz, S. A., Senter, P. D., Wahl, A. F., Schutten, M. M., Shah, D. K., Haddish‐Berhane, N., & Kabbarah, O. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12499 · Cited by 76
Sensi, M., & Anichini, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2682 · Cited by 76
Goldmacher, V. S., & Kovtun, Y. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.98 · Cited by 73
Woo, H. J., Lotz, M. M., Jung, J. U., et al. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55075-4 · Cited by 69
Identification of the sites of IgG catabolism in the rat
Henderson, L. A., Baynes, J., & Thorpe, S. R. (1982) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(82)90272-7 · Cited by 69
E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar, V., Law, D. A., Ibsen, E. M., Breinberg, D., Cass, K. M., DuBridge, R. B., Evangelista, F., Henshall, S. M., Hevezi, P. A., Miller, J. C., et al. (2003) · PubMed · Cited by 65
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering
Wang, Y., Tian, Z., Diraviyam, T., & Zhang, X. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2013.875030 · Cited by 64
Cancer therapy with bispecific antibodies: Clinical experience.
Thakur, A. B., & Lum, L. G. (2010) · PubMed · Cited by 63
Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma
Shin, W., Kwon, J., Lee, H. W., Kang, M. C., Na, H. K., Lee, S., & Park, J. H. (2013) · Cancer Science · doi:10.1111/cas.12194 · Cited by 63
A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments
Ferl, G. Z., Kenanova, V. E., Wu, A. M., & DiStefano, J. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0072 · Cited by 62
Understanding and circumventing resistance to anticancer monoclonal antibodies
Reslan, L., Dalle, S., & Dumontet, C. (2009) · mAbs · doi:10.4161/mabs.1.3.8292 · Cited by 60
CC‐1065とデュオカルマイシン 新種の天然誘導DNAアルキル化剤のかぎの解明
Boger, D. L., & Johnson, D. S. (1995) · Proceedings of the National Academy of Sciences · Cited by 60
Guillemard, V., & Saragovi, H. U. (2004) · Oncogene · doi:10.1038/sj.onc.1207463 · Cited by 57
Chow, A. Y. M. (2010) · Cited by 57
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
Stasi, R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.527 · Cited by 54
Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy
Lee, T.-Y., Sjin, R. M. T. T., Movahedi, S., Ahmed, B., Pravda, E. A., Lo, K.-M., Gillies, S. D., Folkman, J., & Javaherian, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1530 · Cited by 53
Antibody-Based Vascular Tumor Targeting
Schliemann, C., & Neri, D. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-78281-0_12 · Cited by 52
Beeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
Feld, J., Barta, S. K., Schinke, C., Braunschweig, I., Zhou, Y., & Verma, A. K. (2013) · Oncotarget · doi:10.18632/oncotarget.924 · Cited by 47
Macromolecular Anticancer Therapeutics
Reddy, L. H., & Couvreur, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-0507-9 · Cited by 46
Identification of EpCAM as a Molecular Target of Prostate Cancer Stroma
Mukherjee, S., Richardson, A. M., Rodriguez‐Canales, J., Ylaya, K., Erickson, H. S., Player, A. N., Kawasaki, E. S., Pinto, P. A., Choyke, P. L., Merino, M. J., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.090013 · Cited by 46
Fourth World Antibody-Drug Conjugate Summit: February 29–March 1, 2012, Frankfurt, Germany
Beck, A., Lambert, J. M., Sun, M. M. C., & Lin, K. (2012) · mAbs · doi:10.4161/mabs.21697 · Cited by 41
Asano, R., Kumagai, T., Nagai, K., Taki, S., Shimomura, I., Arai, K., Ogata, H., Okada, M., Hayasaka, F., Sanada, H., et al. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt009 · Cited by 41
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer
Drachman, J. G., & Senter, P. D. (2013) · Hematology · doi:10.1182/asheducation-2013.1.306 · Cited by 35
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Lo‐Coco, F., Ammatuna, E., & Noguera, N. I. (2006) · PubMed · Cited by 30
Ferreira, R. J., Ferreira, M. U., & dos Santos, D. J. V. A. (2014) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1196 · Cited by 30
Picking the Optimal Target for Antibody-Drug Conjugates
Mathur, R., & Weiner, G. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e103 · Cited by 27
Tercel, M., McManaway, S. P., Leung, E. Y., Liyanage, H. D. S., Lu, G., & Pruijn, F. B. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208373 · Cited by 26
Asano, R., Shimomura, I., Konno, S., Ito, A., Masakari, Y., Orimo, R., Taki, S., Arai, K., Ogata, H., Okada, M., et al. (2014) · mAbs · doi:10.4161/mabs.29445 · Cited by 24
In vivobehaviour of antibody–drug conjugates for the targeted treatment of cancer
Xie, H., & Blättler, W. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.3.281 · Cited by 24
Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3
Kamada, H., Taki, S., Nagano, K., Inoue, M., Ando, D., Mukai, Y., Higashisaka, K., Yoshioka, Y., Tsutsumi, Y. M., & Tsunoda, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.12.030 · Cited by 23
Thudium, K. E., Bilic, S., Leipold, D. D., Mallet, W. G., Kaur, S., Meibohm, B., Erickson, H. K., Tibbitts, J., Zhao, H., & Gupta, M. (2013) · mAbs · doi:10.4161/mabs.22909 · Cited by 16
Onadeko, B. O., Khadadah, M., Abdella, N., Mukhtar, M., Mourou, M., Qurtom, M., Samad, M., & Al-Shayeb, A. (2005) · Medical Principles and Practice · doi:10.1159/000081921 · Cited by 16
Antibody–Cytotoxic Compound Conjugates for Oncology
Vater, C. A., & Goldmacher, V. S. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_9 · Cited by 11
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Molecular targeted therapy: Treating cancer with specificity
Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.034 · Cited by 1,067
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Metadata
- Authors
- Peters, C., & Brown, S.
- Venue
- Bioscience Reports
- Publisher
- Portland Press Ltd.
- Published
- 2015-07-14
- Volume
- 35
- Issue
- 4
- ISSN
- 0144-8463 (ISSN-L)
- 1573-4935
- OpenAlex
- W2248346391
- Cited by
- 492
- References
- 198
- FWCI
- 30.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.